Eurofins Scientific Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Gilles Martin

Chief executive officer

€1.4m

Total compensation

CEO salary percentage	97.6%
CEO tenure	36.3yrs
CEO ownership	0.00001%
Management average tenure	no data
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gilles Martin's remuneration changed compared to Eurofins Scientific's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€1m	€1m	€257m
Sep 30 2023	n/a	n/a	€335m
Jun 30 2023	n/a	n/a	€414m
Mar 31 2023	n/a	n/a	€497m
Dec 31 2022	€1m	€1m	€581m
Sep 30 2022	n/a	n/a	€612m
Jun 30 2022	n/a	n/a	€643m
Mar 31 2022	n/a	n/a	€696m
Dec 31 2021	€1m	€1m	€749m
Sep 30 2021	n/a	n/a	€786m
Jun 30 2021	n/a	n/a	€824m
Mar 31 2021	n/a	n/a	€665m
Dec 31 2020	€1m	€1m	€505m
Sep 30 2020	n/a	n/a	€347m
Jun 30 2020	n/a	n/a	€190m
Mar 31 2020	n/a	n/a	€168m
Dec 31 2019	€1m	€1m	€146m
Sep 30 2019	n/a	n/a	€144m
Jun 30 2019	n/a	n/a	€143m
Mar 31 2019	n/a	n/a	€159m
Dec 31 2018	€1m	€1m	€175m

Compensation vs Market: Gilles's total compensation ($USD1.45M) is below average for companies of similar size in the Austrian market ($USD4.43M).

Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.

CEO

Gilles Martin (60 yo)

36.3yrs

Tenure

€1,351,000

Compensation

Dr. Gilles G. Martin, Ph D., serves as the Chief Executive Officer at Eurofins Scientific, Inc. Dr. Martin serves as Chief Executive Officer of Eurofins Nihon Kankyo K.K. and Eurofins Scientific Group. He...

Board Members

Name	Position	Tenure	Compensation	Ownership
Gilles Martin	Chairman of the Board & CEO	36.3yrs	€1.35m	0.000010% € 1.1k
Valerie Hanote	Executive Director	34.3yrs	€400.69k	0.000010% € 1.1k
Yves-Loïc Martin	Non-Executive Director	32.3yrs	€33.00k	0.075% € 8.2m
Patrizia Luchetta	Independent Non-Executive Director	7yrs	€71.50k	no data
Ivo Rauh	Independent Non-Executive Director	3yrs	€55.00k	no data
Fereshteh Pouchantchi	Independent Non-Executive Director	10yrs	€44.00k	0.0033% € 357.2k
Evie Roos	Independent Non-Executive Director	3yrs	€66.00k	0.00031% € 33.9k
Pascal Rakovsky	Lead Independent Non-Executive Director	3.8yrs	€93.50k	no data

8.5yrs

Average Tenure

59.5yo

Average Age

Experienced Board: ESF's board of directors are considered experienced (8.5 years average tenure).

Eurofins Scientific Management

Management criteria checks 3/4

Key information

Recent management updates

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

Recent updates

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €1.61 (vs €3.02 in FY 2022)

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €0.79 (vs €1.52 in 1H 2022)

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Upcoming dividend of €1.00 per share at 1.8% yield

Now 22% undervalued after recent price drop

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Now 20% undervalued after recent price drop

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Eurofins Scientific SE to Report Q3, 2022 Results on Oct 18, 2022

Now 22% undervalued after recent price drop

Eurofins Scientific SE (ENXTPA:ERF) signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Eurofins Scientific SE (ENXTPA:ERF) acquired Wessling Hungary Kornyezetvedelmi, Elelmiszerbiztonsagi, Egeszsegvedelmi Es Minosegugyi Sz.

First half 2022 earnings released: EPS: €1.62 (vs €2.09 in 1H 2021)

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Upcoming dividend of €1.00 per share

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire unknown majority stake in Ajal for Laboratories from Saudi Ajal Laboratories.

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc.

Health Canada Approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Eurofins Scientific SE to Report Q1, 2022 Results on Apr 21, 2022

Eurofins’ empowerDX Launches PFAS Exposure™ in the U.S, the First at-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Eurofins Technologies Launches New Lateral Flow Reader Rapidscan ST5-W as Single Platform Validated for Multiple Food and Environmental Rapid Tests

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

First half 2021 earnings released: EPS €2.17 (vs €0.43 in 1H 2020)

Eurofins Scientific SE (ENXTPA:ERF) acquired bioskin GmbH.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 India Sars-Cov-2 Variant

Eurofins Scientific Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Full year 2020 earnings released: EPS €2.71 (vs €0.82 in FY 2019)

Revenue beats expectations

Eurofins Environment Testing America Expands Reporting to 75 Compounds

Eurofins Scientific SE to Report Fiscal Year 2020 Results on Mar 01, 2021

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire Beacon Discovery, Inc.

Eurofins Adds Virus Variant Distinction to its Sars-Cov-2 Monitoring Solution for Wastewater, Food and Environmental Surfaces

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

New 90-day high: €80.51

New 90-day high: €73.16

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 Full-Length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

Eurofins U.S. Clinical Diagnostic Laboratories At-Home COVID-19 Test Now Being Offered in All 50 States

Eurofins Technologies Launches New and Improved Lateral Flow Device Product Line for Allergen Detection in Foodstuffs and Environmental Samples

Eurofins Scientific SE (ENXTPA:ERF) acquired Taiyo Techno Research.

Eurofins Launches Sensitive, Fast and Cost-effective High Throughput SARS-CoV-2 Test Kits for Widely Available Sanger Sequencing Equipment

Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test

Eurofins Scientific Se Launches Europe’S First Validated Test Method to Evaluate Filtration Capacity of Masks for Sars-Cov-2